ALT5 Sigma (NASDAQ:ALTS) Shares Down 5.1% – Here’s Why

Posted by Defense World Staff on Dec 31st, 2025

Shares of ALT5 Sigma Corporation (NASDAQ:ALTS – Get Free Report) were down 5.1% during mid-day trading on Tuesday . The company traded as low as $1.09 and last traded at $1.12. Approximately 5,467,386 shares changed hands during mid-day trading, an increase of 58% from the average daily volume of 3,460,080 shares. The stock had previously closed at $1.18.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ALT5 Sigma in a report on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Get Our Latest Report on ALTS

ALT5 Sigma Stock Performance

The company’s 50 day moving average price is $1.74 and its two-hundred day moving average price is $4.38. The company has a debt-to-equity ratio of 1.45, a quick ratio of 0.88 and a current ratio of 0.88.

Institutional Trading of ALT5 Sigma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in ALT5 Sigma by 775.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,126,395 shares of the company’s stock worth $16,480,000 after acquiring an additional 5,426,519 shares in the last quarter. Crcm LP purchased a new stake in shares of ALT5 Sigma in the third quarter worth $6,220,000. Prelude Capital Management LLC purchased a new stake in shares of ALT5 Sigma in the third quarter worth $6,216,000. NWI Management LP bought a new stake in shares of ALT5 Sigma during the 3rd quarter valued at $4,842,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of ALT5 Sigma during the 3rd quarter valued at $4,697,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.

About ALT5 Sigma

(Get Free Report)

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.